Search clinical trials for: G2019S LRRK2 Mutation

Total 3276 results

Escape Bio, Inc.
Engage Health Inc.; Sano

Terminated

Parkinson's Disease G2019S LRRK2 Genetic Testing Program

Parkinson's Disease

United States
Icahn School of Medicine at Mount Sinai
Massachusetts General Hospital; National Institute of Neurological Disorders...

Recruiting

LRRK2, GBA and Other Genetic Biomarkers in Eastern European (Ashkenazi) Jews With and Without Parkinson's Disease (BioPD)

Parkinson Disease | GBA Gene Mutation | LRRK2

United States
Escape Bio, Inc.
Momentum Pharma; Science 37

Terminated

A Natural History Study of Patients With G2019S LRRK2 Parkinson's Disease

Patients With Parkinson's Disease (PD) Caused by the p.Gly2019Ser (G2019S) Pathogenic Mutation of the Leucine-Rich Repeat Kinase 2 (LRRK2) Gene

United States
Institut National de la Santé Et de la Recherche...

Unknown

Clinical, Molecular and by Neuroimaging of LRRK2 Mutations (LRRK2)

Parkinson's Disease

France
Xuanwu Hospital, Beijing
Michael J. Fox Foundation for Parkinson's Research

Completed

LRRK2 Activity and Markers of Parkinson's Disease in G2385R Carriers

Parkinson Disease

China
Nantes University Hospital

Terminated

Study of the Enteric Nervous System Using Colonic Biopsies in Parkinson Patients With LRRK2 Mutation (EnteroLarc)

Parkinson's Disease

France
University of Malaya
Michael J. Fox Foundation for Parkinson's Research; University of Dundee; Nextcea... and other collaborators

Unknown

LRRK2 G2385R Leucocyte and Urine Biomarker Study (LRRK2 G2385R)

Parkinson Disease

Malaysia
King's College London
GlaxoSmithKline

Completed

Molecular Pathology and Neuronal Networks in LRRK2 Parkinson's Disease

Parkinson Disease | Idiopathic Parkinson Disease | Parkinson Disease, PARK8

United Kingdom
GlaxoSmithKline

Terminated

LRRK2 Mutation and Parkinson's Disease

Parkinson Disease

United Kingdom
Indiana University
Michael J. Fox Foundation for Parkinson's Research

Completed

PROGENI (Parkinson's Research: The Organized Genetics Initiative) Family Study of LRRK2 (Leucine-rich Repeat Kinase 2) (PROGENI)

Parkinson Disease

United States, Canada
Assistance Publique - Hôpitaux de Paris
France Parkinson Association

Unknown

Measure of Microglial Activation in the Brain of Parkinson Disease Patients With PET (INFLAPARK)

Healthy Controls | Parkinson's Disease With LRRK2 Mutation | Parkinson's Disease Without LRRK2 Mutation

France
CENTOGENE GmbH Rostock

Recruiting

Rostock International Parkinson's Disease Study (ROPAD) (ROPAD)

Parkinson´s Disease

Spain, Israel, United Kingdom, United States, Germany, Albania, Belgium, Brazil, Canada, France, Greece, Italy, Portugal, Turkey, Norway
Michael J. Fox Foundation for Parkinson's Research
University Health Network, Toronto; University of Rochester; Indiana University

Completed

FoxBioNet: ECV (Extracellular Vesicle) 004

Parkinson Disease

United States
Denali Therapeutics Inc.

Completed

Study to Evaluate DNL201 in Subjects With Parkinson's Disease

Parkinson Disease

United States
Biogen

Completed

Study to Evaluate DNL151 in Subjects With Parkinson's Disease

Parkinson's Disease

Belgium, United States, United Kingdom, Netherlands
Michael J. Fox Foundation for Parkinson's Research
University Health Network, Toronto; University of Rochester; Indiana University

Completed

Fox BioNet Project: ECV-003

Parkinson Disease

United States
Michael J. Fox Foundation for Parkinson's Research
University Health Network, Toronto; University of Rochester; Indiana University

Completed

Fox BioNet Project: LRRK2-002

Parkinson Disease

United States
University of Luebeck
CENTOGENE GmbH Rostock

Unknown

LIPAD - LRRK2 International Parkinson's Disease Study (LIPAD)

Parkinson's Disease and Parkinsonism

Germany
Tel-Aviv Sourasky Medical Center

Unknown

Ioflupane I123 (DaTSCAN) and Positron Emission Tomography-computed Tomography Fludeoxyglucose (PET-CT FDG) to Assess Brain Function of Parkinson Patients With Different Genetic Characteristics

Parkinson Disease

Israel
Xiangya Hospital of Central South University

Recruiting

Chinese PD-LRRK2 Registry

Parkinson Disease

China
University of Rochester
Michael J. Fox Foundation for Parkinson's Research; Emerald Innovations

Active, not recruiting

Objective, Passive Assessment of LRRK2 Carriers (OPAL)

Parkinson Disease

United States
University of Alabama at Birmingham
National Institute of Neurological Disorders and Stroke (NINDS)

Completed

LRRK2 and Other Novel Exosome Proteins in Parkinson's Disease

Parkinson's Disease

United States
Tel-Aviv Sourasky Medical Center
United States Department of Defense

Recruiting

Evaluation of the Frequency and Severity of Sleep Abnormalities in Patients With Parkinson's Disease

Parkinson Disease | GBA Gene Mutation | Leucine-rich Repeat Kinase 2 (LRRK2) Gene Mutation

Israel
Servier

Completed

Non-drug Treatment Study in Parkinson's Disease Patients and Healthy Volunteers to Collect Biological Samples in Order to Assess ex Vivo the Activity of Candidate Therapies and Develop Novel Analytical Methods for Biomarkers (IRIS-CLE-LRRK2)

Parkinson Disease

France
Biogen
Denali Therapeutics Inc.

Terminated

A Study to Assess if BIIB122 Tablets Are Safe and Can Slow Worsening of Early-Stage Parkinson's Disease in Participants With Specific LRRK2 Genetic Variants Between the Ages of 30 and 80 Using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (LIGHTHOUSE)

Parkinson Disease

United States, Italy, Spain, Germany, France, United Kingdom
Pfizer

Not yet recruiting

A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.

Carcinoma, Non-Small-Cell Lung | Colorectal Neoplasms | Carcinoma, Pancreatic Ductal
Revolution Medicines, Inc.

Recruiting

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

Colorectal Cancer | Pancreatic Ductal Adenocarcinoma | Gastrointestinal Cancer | CRC | Metastatic Pancreatic Ductal Adenocarcinoma | PDAC

United States
Peking University Cancer Hospital & Institute

Not yet recruiting

First Human Trial of Targeting MDM2/MDMX PET Imaging

Nuclear Medicine | MDM2/MDMX Gene Mutation | Positron Emission Tomography Imaing
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation

Thyroid Gland Follicular Carcinoma | Thyroid Gland Papillary Carcinoma | Thyroid Gland Oncocytic Carcinoma

United States
Massachusetts General Hospital

Not yet recruiting

Ziftomenib Maintenance Post Allo-HCT

Acute Myeloid Leukemia | Acute Myeloid Leukemia in Remission | NPM1 Mutation | KMT2A Rearrangement

United States
Novartis Pharmaceuticals

Not yet recruiting

A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE) (SPARKLE)

Sickle Cell Disease
Splice Bio

Recruiting

An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene (POLARIS)

Stargardt Disease | Stargardt's Disease | STGD1 | Stargardt
Daping Hospital and the Research Institute of Surgery...

Not yet recruiting

Osimertinib and Etoposide as First-Line Treatment in Osimertinib-Resistant Advanced EGFR-Mutant NSCLC

Non Small Cell Lung Cancer | Non Small Cell Lung Cancer Stage IIIB | EGFR Gene Mutation | Non-small Cell Lung Cancer Stage IV
Assiut University

Not yet recruiting

Detection of Krupple Like Factor -1(KLF1/ EKLF) DNA Mutations in Beta Thalassemia Patients

EKLF Mutations in Beta Thalassemia Patients
Centre Hospitalier Universitaire Dijon

Not yet recruiting

Study of the Value of hPG80 (Circulating Progastrin) for the Diagnosis of Neuroendocrine Tumours in Patients With an MEN1 Mutation (PRO-NEM1)

Neuroendocrine Tumors | MEN1 Mutation

France
Wuxi People's Hospital

Recruiting

Clinical Efficacy of Tumour Treatment Vaccine (TTV) Combined With PD-1 in the Treatment of Relapsed Refractory Advanced Solid Tumours

Cancer | PD-L1 Gene Mutation

China
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations

Non-Small Cell Lung Cancer With HER2- Mutations

China
Quanta Therapeutics

Not yet recruiting

QTX3046 in Patients With KRAS G12D Mutations

Advanced Solid Tumor
Novartis Pharmaceuticals

Not yet recruiting

Clinical Study of Asciminib in Previously Treated Indian Patients With Ph+ CML-CP Without T315I Mutation and in Patients With Ph+ CML-CP With T315I Mutation (ASC4INDIA)

Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase
Centre Leon Berard

Not yet recruiting

Tobacco, Alcohol and Cancerization of the Oral Mucosa (TACO) (TACO)

Oral Squamous Cell Carcinomas

France
Jacobio Pharmaceuticals Co., Ltd.

Not yet recruiting

JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation

Advanced Non-squamous Non-small-cell Lung Cancer | Metastatic Non-squamous Non Small Cell Lung Cancer
AstraZeneca

Not yet recruiting

Prevalence of Emerging Treatment-induced Mutations in Metastatic ER-positive Breast Cancer. (Pangeia-2)

Metastatic Breast Cancer

Brazil
AstraZeneca
Daiichi Sankyo

Not yet recruiting

A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung15)

Metastatic Non-small Cell Lung Cancer
M.D. Anderson Cancer Center

Not yet recruiting

A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations

Metastatic Colorectal Cancer | KRAS G12C Mutations

United States
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer

Endometrial Carcinoma | Recurrent or Metastatic | TP53 Mutation

China
Assistance Publique - Hôpitaux de Paris
Centre Leon Berard; Institut National de la Santé Et de la Recherche Médicale... and other collaborators

Not yet recruiting

Impact of Environmental Exposures on Tumor Risk in SDHx-mutation Carriers (PGLEXPO2)

Environmental Exposure | SDH Gene Mutation | SDH-Related Familial Paraganglioma | SDHx-Related Syndromes

France
Azienda Ospedaliero-Universitaria di Modena

Recruiting

Assessing Clinical Features and Outcome of Breast Cancer in PALB2 Mutation Carriers: the Palbreast Study (PALBREAST)

Breast Cancer

Italy
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

A Multicentre Prospective Cohort Study: Intensive Adjuvant Therapy for TNBC With BRCA Gene Mutation

Early-stage Triple-negative Breast Cancer With BRCA1/2 Mutations

China
858 Therapeutics, Inc.

Recruiting

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies (ERADIC8)

Breast Cancer | Gastric Cancer | Colorectal Cancer | Ovarian Cancer | Prostate Cancer | Endometrial Cancer | Epithelial Ovarian Cancer | BRCA1 Mutation | BRCA2 Mutation | Advanced or Metastatic Solid Tumors | ER+ Breast Cancer | Castrate Resistant Prostate Cancer | BRCA Mutation

United States
Radboud University Medical Center

Not yet recruiting

International Registration of Isolated STIC: to Report and Investigate the Risk of Serous Peritoneal Carcinomatosis (STICRISC)

Peritoneal Carcinoma | Ovarian Carcinoma | Serous Tubal Intraepithelial Carcinoma | BRCA Mutation

Search clinical trials for: G2019S LRRK2 Mutation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Trinidad & Tobago

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations